Stock Screener App

무료 -

설치하다

2.985

0.33% 0.005

Fate Therapeutics Inc (FATE)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

Fate Therapeutics Inc 주식(FATE)의 최신 뉴스

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - The Manila Times

Fate Therapeutics lines up four investor conferences in Q3 - Stock Titan

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Index - marketscreener.com

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index - marketscreener.com

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Value Benchmark - marketscreener.com

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index - marketscreener.com

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Value Benchmark - marketscreener.com

Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade

Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History - Benzinga

F6T Forecast — Price Target — Prediction for 2027 - TradingView

Fate Therapeutics sets out next steps, biotech stock in focus after cash preservation move - AD HOC NEWS

Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T) - TradingView

Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis - TradingKey

Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T) - TradingView

Fate Therapeutics, Inc. Actuals & Estimates (NASDAQ:FATE) - TradingView

Enterprise value to revenue forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView

Fate Therapeutics, Inc. Actuals & Estimates (FWB:F6T) - TradingView

Price to earnings forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView

FATE Forecast — Price Target — Prediction for 2027 - TradingView

Fate Therapeutics Inc (FATE) Institutional Confidence - TradingKey

H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Fate Therapeutics’s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE) - Seeking Alpha

Fate Therapeutics Inc (FATE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities - The Globe and Mail

Fate Therapeutics Inc (FATE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Fate Therapeutics Inc (FATE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Fate Therapeutics Inc (FATE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

FATE Stock Price, Quote & Chart - ChartMill

Fate Therapeutics Shareholders Back Directors and Governance Plans - The Globe and Mail

Redmile director nominee awarded 87,900 Fate Therapeutics (FATE) stock options - Stock Titan

Fate Therapeutics (FATE) director granted 87,900 stock options at $2.06 - Stock Titan

Director Yuan Xu receives 87,900 Fate Therapeutics (FATE) stock options at $2.06 - Stock Titan

FATE Therapeutics (NASDAQ: FATE) director awarded 87,900 stock options as equity pay - Stock Titan

Fate Therapeutics (FATE) director receives 87,900 stock options at $2.06 strike - Stock Titan

Fate Therapeutics (FATE) director receives 87,900 stock options award - Stock Titan

FATE Therapeutics (NASDAQ: FATE) director receives 87,900-share stock option grant - Stock Titan

Director at Fate Therapeutics (NASDAQ: FATE) receives 87,900 stock options grant - Stock Titan

Director Laura Hamill receives 175,800 Fate Therapeutics (FATE) stock options - Stock Titan

Director Laura Hamill files initial Form 3 for FATE Therapeutics (FATE) - Stock Titan

[8-K] FATE THERAPEUTICS INC Reports Material Event - Stock Titan

Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near lo - Ad-hoc-news.de

Fate Therapeutics Appoints Laura Hamill To Board Of Directors - TradingView

Fate Therapeutics appoints Laura Hamill to board of directors - Investing.com

Fate Therapeutics appoints Laura Hamill to board of directors By Investing.com - Investing.com South Africa

Fate Therapeutics Appoints Laura Hamill to Board of Directors - The Manila Times

Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo Finance

Fate Therapeutics (FATE) Q1 2026 Earnings: EPS Beat on Cost Discipline, Pipeline Progress Drives Stock HigherSegment Revenue Breakdown - newsline.com

FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan

H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT - Insider Monkey

5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.

Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo

FATE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $7.00 - GuruFocus

H.C. Wainwright reiterates Fate Therapeutics stock rating on SLE data By Investing.com - Investing.com Canada

Fate Therapeutics Advances Off-the-Shelf CAR T-Cell Therapies for Autoimmune Diseases and Cancer – Clinical Pipeline and 2026 Updates - Minichart

Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline - TipRanks

Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash - TradingView

INSM

$113.18

1.95%

ROIV

$35.27

0.23%

RPRX

$58.09

0.07%

ONC

$305.00

0.85%

MRNA

$82.23

0.32%

RVMD

$190.47

0.31%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개